Welcome to our dedicated page for Karyopharm Therapeutics SEC filings (Ticker: KPTI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Karyopharm Therapeutics Inc. (KPTI) SEC filings page provides access to the company’s official regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Karyopharm is a commercial-stage pharmaceutical company listed on the Nasdaq Global Select Market, and its filings detail financial results, financing arrangements and key corporate developments related to its oncology-focused business.
Among the most relevant documents for investors are Form 10-K annual reports and Form 10-Q quarterly reports, which summarize financial performance, risk factors and updates on Karyopharm’s commercial product XPOVIO (selinexor) and its clinical pipeline in multiple myeloma, endometrial cancer, myelofibrosis and diffuse large B-cell lymphoma (DLBCL). These periodic reports typically discuss revenue from U.S. XPOVIO net product sales and license and royalty revenue from partners, as described in the company’s public communications.
The company also files numerous Form 8-K current reports to describe material events. Recent 8-K filings referenced in the provided information include disclosures of quarterly financial results, strategic financing transactions involving senior secured term loans and 9.00% convertible senior notes due 2028 and 2029, and the issuance of equity and warrants in private placements. Other 8-Ks cover topics such as board changes, workforce reductions and the provision of “cleansing materials” to potential investors during financing discussions.
Investors tracking capital structure and liquidity can review exhibits to these filings, which describe credit and guaranty agreements, note purchase agreements, warrant terms and registration rights agreements. For governance and compensation matters, additional filings may include proxy statements and equity award disclosures, such as inducement grants reported under Nasdaq Listing Rule 5635(c)(4).
On this page, Stock Titan supplements raw EDGAR documents with AI-powered summaries that highlight the main points of lengthy filings, helping readers quickly understand changes in debt, equity, cash runway expectations, and updates on Karyopharm’s clinical and commercial programs. Real-time updates ensure that new 10-Ks, 10-Qs, 8-Ks and other forms appear as they are filed, while specialized views can surface insider-related forms such as Form 4 when available.
Karyopharm Therapeutics Inc. executive Sohanya Cheng, EVP & Chief Commercial Officer, received an award of 32,415 shares of common stock in the form of restricted stock units on January 31, 2026. The RSUs were granted at $0 per share under the company’s 2022 Equity Incentive Plan.
The RSUs convert into common stock on a one-for-one basis, with 50% vesting on January 31, 2027 and the remaining 50% vesting on January 31, 2028. Following this grant, Cheng beneficially owns 111,921 shares of Karyopharm common stock in direct ownership.
Karyopharm Therapeutics reported that its EVP & Chief Medical Officer, Reshma Rangwala, received an award of 32,415 restricted stock units (RSUs) of common stock on January 31, 2026 at a price of $0 per share. The RSUs were granted under the company’s 2022 Equity Incentive Plan and convert into common stock on a one-for-one basis. Half of the shares vest on January 31, 2027, with the remaining half vesting on January 31, 2028. Following this award, Rangwala beneficially owns 61,805 shares of Karyopharm common stock directly.
Karyopharm Therapeutics Inc. reported an equity compensation award to its EVP, CFO & Treasurer, Lori Macomber. She received 32,415 restricted stock units (RSUs) of Karyopharm common stock at a grant price of $0.
The RSUs convert into common stock on a one-for-one basis. They vest in two equal installments, with 50% vesting on January 31, 2027 and the remaining 50% on January 31, 2028. Following this grant, Macomber beneficially owns 86,731 shares of Karyopharm common stock.
Karyopharm Therapeutics Inc. executive Michael Mano, EVP, CLO & Secretary, received an equity award of 32,415 shares of common stock on January 31, 2026. The award was granted at a price of $0 per share under the company’s 2022 Equity Incentive Plan as restricted stock units.
The RSUs convert into common stock on a one-for-one basis and vest over time, with 50% of the shares vesting on January 31, 2027 and the remaining 50% vesting on January 31, 2028. Following this grant, Mano directly beneficially owns 97,490 shares of Karyopharm common stock.
Karyopharm Therapeutics Inc. executive vice president and chief development officer Stuart Poulton reported an award of 32,415 shares of common stock on January 31, 2026. These were granted as restricted stock units under the company’s 2022 Equity Incentive Plan at a price of $0 per share.
The RSUs convert into common stock on a one-for-one basis. Half of the award is scheduled to vest on January 31, 2027, and the remaining half on January 31, 2028. Following this grant, Poulton beneficially owns 99,807 shares of Karyopharm common stock in direct ownership.
Affinity Asset Advisors, LLC and Michael Cho report beneficial ownership of 1,713,092 shares of Karyopharm Therapeutics Inc. common stock, representing 8.6% of the outstanding class as of January 22, 2026. This total includes 1,573,517 shares issuable upon exercise of warrants.
The warrants are subject to a 9.99% beneficial ownership limitation, which caps how many shares can be acquired through exercise relative to Karyopharm’s outstanding stock. The ownership percentages are calculated using 19,883,800 shares of common stock, combining currently outstanding shares and the warrant shares counted for this filing.
Karyopharm Therapeutics’ Chief Accounting Officer Kristin Abate reported the vesting of performance-based restricted stock units and a small share sale. On January 27, 2026, 92 shares of common stock were acquired at $0.0 upon PSUs vesting tied to revenue and total shareholder return milestones.
On January 28, 2026, Abate sold 50 shares of common stock at $7.03 per share to cover withholding tax from the PSU vesting under a pre-established automatic sale plan, described as non-discretionary. After these transactions, she directly owned 22,622 shares of Karyopharm common stock.
Karyopharm Therapeutics Inc.'s Chief Accounting Officer, Kristin Abate, reported an automatic sale of company stock. On 01/21/2026, she sold 265 shares of common stock at $5.96 per share, leaving her with 22,580 shares held directly after the transaction.
The filing explains that this was a broker-assisted sale executed under a durable automatic sale instruction plan adopted on May 27, 2021. The sale was made solely to cover withholding tax liabilities arising from the vesting of restricted stock units and is described as not a discretionary trade by the reporting person.
Karyopharm Therapeutics released preliminary, unaudited 2025 results, expecting total revenue of approximately $145 million for the year, including license and royalty income. For the quarter ended December 31, 2025, it anticipates total revenue of about $33 million.
The company expects U.S. XPOVIO net product revenue of roughly $115 million for 2025, including about $32 million in the fourth quarter. Karyopharm also projects cash, cash equivalents, restricted cash and investments of around $64 million as of December 31, 2025, and believes its existing liquidity, together with expected XPOVIO sales and license revenue, will fund planned operations into the second quarter of 2026.
Karyopharm Therapeutics Inc. is calling a special virtual stockholder meeting on February 18, 2026 to vote on increasing its authorized capital. The company seeks to raise total authorized shares from 58,333,333 to 111,000,000 and authorized common stock from 53,333,333 to 106,000,000 to support future financing and strategic needs. As of December 23, 2025, 18,310,283 common shares were outstanding and 42,747,918 were issued or reserved, leaving 10,585,415 unreserved shares. Management explains that it is nearing the current limit, expects its existing cash and revenue to fund operations only into the second quarter of 2026, and that its ability to remain a going concern depends on raising additional capital. Stockholders will also vote on allowing adjournment of the meeting to solicit more proxies if support for the share increase is initially insufficient.